卫材(中国)药业有限公司

卫材(中国)药业有限公司 company information, Employees & Contact Information

Updated June 2026

Quick answer

卫材(中国)药业有限公司 is a Pharmaceutical Manufacturing company and founded in 1941. It has approximately 455 employees on record. Contact data was last refreshed in June 2026. Find 卫材(中国)药业有限公司's verified employee emails, phone numbers, headquarters address, and key decision makers below.

卫材在华企业隶属于卫材株式会社,卫材株式会社是一家以研究开发医药产品为主的跨国公司,总部设在日本东京,中国区总部位于上海。 卫材自上世纪90年代初进入中国市场以来顺利发展壮大,在华总注册资本10,854万美金,成员企业包括卫材(中国)投资有限公司、卫材(中国)药业有限公司、卫材(辽宁)制药有限公司、卫材(苏州)贸易有限公司、京颐卫享(上海)健康产业发展有限公司(合资)等,形成以神经科学、肿瘤(特药)、消化肝病为重点领域,拓展仿制药等其它领域,销售多达数十种药品和其它产品。 2018年位于苏州工业园区兴浦路的新工厂正式运营,厂房面积2.3万平米,设计产能年制剂30亿片及包装50亿片,产能得到迅速提升。作为集团主力工厂之一,未来苏州工厂生产的产品除了满足中国市场需求,还将供应东亚、东南亚、中东、中南美洲和欧洲等23个国家和地区。 卫材所有在华企业秉承hhc(human health care,关心人类健康)企业宗旨,以Compliance(遵守道德)为行为准则,以GMP为质量标准,向患者及其家属提供高质、环保、安全和满意的产品和服务。 同时,积极承担企业社会责任,2020年为抗击新冠肺炎疫情累计捐赠超过1500万元的现金和医疗物资;自2000年至今,已奖励和资助超过10所医药类高等院校学生2386 人次,总计奖励资助金额超过900万元;自2013年至今,与人口福利基金会合作“记得我爱你黄手环”项目捐赠金额超过500万元,已惠及25万高风险的老年痴呆患者;自2014年至2019年,通过“卫生三下乡”活动捐赠金额近300万元的医药品;到目前为止,与中国初级卫生保健基金会合作向肿瘤患者和家庭无偿提供了超过20亿元药品,解决患者的家庭负担,极大提升了患者使用创新药的可及性和可负担性,并连续数年获得“上海市文明单位”、“中国杰出雇主”、 “大苏州最佳雇主”、“中国医药工业百强”、“推进医学公益践行企业使命”年度企业等荣誉称号。

Company Details

Employees
455
Founded
1941
Address
上海, 上海 200000, Cn
Industry
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing
Medicinal and Botanical Manufacturing
Pharmaceutical Preparation Manufacturing
In-Vitro Diagnostic Substance Manufacturing
Biological Product (except Diagnostic) Manufacturing
HQ
上海, 上海
Looking for a particular 卫材(中国)药业有限公司 employee's phone or email?

卫材(中国)药业有限公司 Questions

News

Early Alzheimer’s Patients Continue to Benefit from Four Years of LEQEMBI® (lecanemab-irmb) Therapy New Clinical Data Presented at AAIC - Eisai Co., Ltd.

Early Alzheimer’s Patients Continue to Benefit from Four Years of LEQEMBI® (lecanemab-irmb) Therapy New Clinical Data Presented at AAIC Eisai Co., Ltd.

New Data Presented at AAIC Demonstrates Investigational LEQEMBI® (lecanemab-irmb) 360 mg Subcutaneous Maintenance Dosing Could Offer a New Option for Ongoing Treatment of Early Alzheimer’s Disease - Eisai Co., Ltd.

New Data Presented at AAIC Demonstrates Investigational LEQEMBI® (lecanemab-irmb) 360 mg Subcutaneous Maintenance Dosing Could Offer a New Option for Ongoing Treatment of Early Alzheimer’s Disease Eisai Co., Ltd.

Eisai Rated “A”, the Highest Rating by CDP in the Categories of Climate Change and Water Security - Eisai Co., Ltd.

Eisai Rated “A”, the Highest Rating by CDP in the Categories of Climate Change and Water Security Eisai Co., Ltd.

Digital Asset Library - Eisai US

Digital Asset Library Eisai US

EISAI COMPLETES CONSTRUCTION OF ITS NEW INJECTION/RESEARCH BUILDING AT KAWASHIMA INDUSTRIAL PARK IN JAPAN | News Release:2022 - Eisai Co., Ltd.

EISAI COMPLETES CONSTRUCTION OF ITS NEW INJECTION/RESEARCH BUILDING AT KAWASHIMA INDUSTRIAL PARK IN JAPAN | News Release:2022 Eisai Co., Ltd.

Corporate Venture Capital - Eisai Co., Ltd.

Corporate Venture Capital Eisai Co., Ltd.

The First 80 Years | Eisai Co., Ltd. - Eisai Co., Ltd.

The First 80 Years | Eisai Co., Ltd. Eisai Co., Ltd.

Eisai’s Efforts on Global Health ― An Interview of Scientists Working on Drug Discovery - Eisai Co., Ltd.

Eisai’s Efforts on Global Health ― An Interview of Scientists Working on Drug Discovery Eisai Co., Ltd.

Compliance and Risk Management - Eisai Co., Ltd.

Compliance and Risk Management Eisai Co., Ltd.

ANTIEPILEPTIC DRUG FYCOMPA® INJECTION FORMULATION LAUNCHED IN JAPAN - Eisai Co., Ltd.

ANTIEPILEPTIC DRUG FYCOMPA® INJECTION FORMULATION LAUNCHED IN JAPAN Eisai Co., Ltd.

Initiatives for Improving Access to Medicines - Eisai Co., Ltd.

Initiatives for Improving Access to Medicines Eisai Co., Ltd.

Dementia - Eisai Co., Ltd.

Dementia Eisai Co., Ltd.

Production and Logistics (Demand Chain Systems) - Eisai Co., Ltd.

Production and Logistics (Demand Chain Systems) Eisai Co., Ltd.

Chapter 6 Breaking into the Top 20 Worldwide - Eisai Co., Ltd.

Chapter 6 Breaking into the Top 20 Worldwide Eisai Co., Ltd.

Alzheimer's Disease Treatment The Aricept R&D Story - Eisai Co., Ltd.

Alzheimer's Disease Treatment The Aricept R&D Story Eisai Co., Ltd.

Top 卫材(中国)药业有限公司 Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant